Showing 8 posts of 8 posts found.


European Commission approves EU’s first peanut allergy treatment

December 21, 2020
Sales and Marketing Aimmune, European Commission, allergy

Aimmune Therapeutics today announced that the European Commission (EC) has approved PALFORZIA as the EU’s first-ever treatment of peanut allergy. …


Nestlé to acquire remaining shares in Aimmune for $2.6 billion

September 2, 2020
Research and Development, Sales and Marketing Aimmune, acquisition, nestle, pharma

Food and drink giant Nestlé has confirmed it is in motion to scoop up the remaining shares in Californian biotech …


Aimmune’s peanut allergy therapy recommended for approval by FDA committee

September 16, 2019
Sales and Marketing Aimmune, FDA, peanut allergy, pharma

The FDA’s Allergenic Products Advisory Committee (APAC) has recommended the use of Aimmune Therapeutics’ AR101, also known by its proposed …


Aimmune’s peanut allergy therapy closes in on approval with promising Phase 3 data

March 26, 2019
Manufacturing and Production, Research and Development AR101, Aimmune, allergy, pharma

Aimmune Therapeutics is gearing up for regulatory review of its investigational food allergy therapy AR101 following the release of new …


FDA halts allergy drug approval process due to government shutdown

January 15, 2019
Research and Development Aimmune, FDA, Trump, governmetn, shutdown

California-based pharma firm, Aimunne Therapeutics has been notified that due to the government shutdown, the US Food and Drug Administration …


Aimmune’s peanut allergy candidate hits main endpoint at Phase 3

February 21, 2018
Research and Development Aimmune, peanut, peanut allergy, pharma

US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …


Peanut allergies? There’s a clinical trial looking to fix that

October 17, 2017
Manufacturing and Production, Research and Development Aimmune, Regeneron, Sanofi, biotech, drugs, peanuts, pharma, pharmaceutical

Aimmune Therapeutics, a biotech company developing treatments for food allergies, announced that it has entered into a clinical trial collaboration …


Nestle backs allergy biotech Aimmune to the tune of $145 million

November 7, 2016
Sales and Marketing Aimmune, allergy therapeutics, nestle

Nestle Health Science has invested $145 million in return for a 15% stake in Aimmune Therapeutics. Aimmune pursues food-allergy therapies …

Latest content